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Abstract
The gene encoding the mu-opioid receptor (OPRM1) is reported to be associated with a range of
substance dependence. Experiments in knockout mice indicate that the mu-opioid receptor may
mediate reinforcing effects of nicotine. In humans, opioid antagonist naltrexone may reduce the
reinforcing effects of tobacco smoking. Additionally, the OPRM1 gene is located in a region showing
linkage to nicotine dependence. The OPRM1 is thus a plausible candidate gene for smoking
behavior. To investigate whether OPRM1 contributes to the susceptibility of smoking initiation and
nicotine dependence, we genotyped 11 SNPs in the gene for 688 Caucasian subjects of lifetime
smokers and nonsmokers. Three SNPs showed nominal significance for smoking initiation and one
reached significance for nicotine dependence. The global test for three-marker (rs9479757-
rs2075572-rs10485057) haplotypes was significant for smoking initiation (p = 0.0022). The same
three-marker haplotype test was marginal (p = 0.0514) for nicotine dependence. These results
suggest that OPRM1 may be involved in smoking initiation and nicotine dependence.
Background
Tobacco use is a leading cause of preventable diseases in
the world and causes nearly 5 million tobacco-related
deaths annually [1]. According to the World Health
Organization, 1.3 billion people are smokers and half of
the smokers in the world today will die of smoking related
diseases [2]. Nicotine is the primary factor responsible for
the addictive behaviors. In last two decades, family, twin
and adoption studies have implicated that genetic factors
strongly influence the behaviors of tobacco use and nico-
tine dependence [3,4]. In the review by Sullivan and Ken-
dler, they estimated that genetic factors accounted for
56% of the variance in the liability of smoking initiation
(SI) and 67% of the variance for progression to nicotine
dependence (ND) [4].
The μ-opioid receptor encoded by the OPRM1 gene is a
key factor contributing to drug addiction [5]. The μ-opi-
oid receptor is a major site of action for endogenous opi-
oid peptides and exogenous opioid drugs. More
interestingly, some non-opioid substances including nic-
otine that have other primary sites of action are likely to
induce the release of endogenous opioid peptides, and
subsequently activate the μ receptor [5]. For instance,
experiments have shown that nicotine causes a release of
endogenous opioids in the brains of rat and mouse [6].
Recent studies using inbred and knockout mice strongly
suggest that the μ-opioid receptor mediates both the pos-
itive and negative reinforcing effects of nicotine. Nicotine-
induced antinociception, reward effects and dependence
are substantially attenuated in mice lacking the μ-opioid
receptor [7,8]. This implies that some aspects of the
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rewarding valence of nicotine require μ opioid receptors.
In humans, opioid receptor antagonist naloxone may
reduce the relative reinforcing effects of nicotine, thus it
has been used as a smoking cessation drug [9-11]. Lerman
and colleagues show that a variant in OPRM1 may predict
the treatment responses to clinical nicotine replacement
therapy. Smokers who have the Asp40 variant in the
OPRM1 gene are likely to have a favorable response to the
treatment [12]. Interestingly, the OPRM1 gene is located
at 6q24-25, about 4 million basepairs from a suggestive
linkage peak of nicotine dependence [13]. All these sug-
gest that the OPRM1 is an attractive candidate gene that
may influence the smoking behavior in humans.
More than 100 SNPs in the human OPRM1 gene have
been identified, some of which have been tested for asso-
ciations with a range of substance dependence [14-19].
Most studies focus on analyzing the variants in coding
regions or 5' UTRs. The Asn40Asp variant or rs1799971 is
one of the most studied polymorphisms in the gene.
However, the results are not consistent. Of the studies
conducted for the gene, many do not have comprehensive
coverage. In this study, we use haplotype-tagging
approach to select SNPs and carry out association analyses
for both individual markers and haplotypes. Our results
indicate that a major haplotype may be involved in
tobacco smoking.
Methods and materials
Subjects
The sample was drawn from two large population-based
twin studies of the Virginia Twin Registry. The sampling
and ascertainment procedures were described elsewhere
[20,21]. In this study, we used a subset of twins of Euro-
pean ancestry and randomly selected one twin from each
pair. All the subjects were unrelated. All individuals were
assessed with basic smoking history, the Fagerstrom Tol-
erance Questionnaire (FTQ) [22] and withdrawal symp-
toms. The FTQ was an eight-item questionnaire (score
range 0–11) widely used to evaluate the severity of nico-
tine dependence. In this study, the non-smokers (NS)
were defined as those who never smoked a cigarette up to
the time of the assessment. Regular smokers with low ND
(Low-ND) were defined as those who smoked at least 5
cigarettes per week for five years and their FTQ scores were
between 0–2 at their lifetime maximum tobacco con-
sumption. Regular smokers with high ND (High-ND)
were those who smoked for five years or more and had an
FTQ score between 7–11. In order to evaluate separately
the influence of OPRM1 on SI and ND, two measure-
ments with overlapping but not identical genetic effects
[21,23], we used this 3-group design. The selection of sub-
jects was based on this design. To estimate the influence
of OPRM1 on SI, we compared the allele and genotype
frequencies between the NS and regular smokers (which
included both Low- and High-ND subjects). For that of
ND, we compared the frequencies between the Low- and
High-ND subjects. Smokers with FTQ scores between 2
and 7 were not used in this dichotomized design. Of the
688 subjects used in this study, 244 were NS, 215 were
Low-ND and 229 were High-ND.
The buccal epithelial cell samples were collected using
standard cytology brushes (Fisher Scientific, Fair Lawn,
New Jersey). DNA was isolated from the brushes as
reported previously [24]. All individuals provided
informed consent for participation in this study. Sixteen
unlinked microsatellite markers were genotyped to assess
the potential population stratification and no evidence of
stratification was found [24].
SNPs selection and genotyping
Eleven SNPs were chosen from the dbSNP and Celera
genomics database with the following criteria: (1) SNPs
located in coding or regulatory regions of the gene or
reported associated with drug dependence in literature;
(2) haplotype-tagged SNPs suggested by HapMap data-
base [25] or SNPbrowser™ Software 3.0 [26] using the
default parameters; and (3) SNPs with minor-allele fre-
quency ≥ 0.10 in the dbSNP database. SNP rs1799971 is a
non-synonymous variant (Asn40Asp) located in exon 1.
Other SNPs are located in intronic regions of OPRM1.
Table 1 listed the characteristics of the selected SNPs.
Genotyping was performed with the TaqMan genotyping
method [27]. Briefly, the PCRs were conducted with 384-
well microplates. To ensure the quality of genotyping,
negative control samples were included in each plate. The
PCRs were performed with 5 ng of genomic DNA, 0.25 μl
of TaqMan assay mix (Applied Biosystems, Inc., Foster
City, CA, USA) and 2.5 μl of TaqMan universal PCR mas-
ter mix in a total reaction volume of 5 μl. After activating
the polymerase and denaturizing DNA by heating at 95°C
for 10 minutes, 40 cycles of 92°C for 15 seconds and
55°C for 1 minute were performed. After the reaction, the
fluorescence intensities of reporter 1 and 2 (reporter
1:VIC, excitation = 520 ± 10 nm, emission = 550 ± 10 nm;
reporter 2: FAM, excitation = 490 ± 10 nm, emission = 510
± 10 nm) were measured by the Analyst fluorescence plate
reader (LJL Biosytems, Sunnyvale, CA). Based on the ratio
of fluorescence intensities, genotypes were scored by a
Euclidean clustering algorithm developed in our labora-
tory [28].
Statistical analysis
To distinguish the effects of the OPRM1 gene on SI and
ND, we made two dichotomous comparisons. For the
effect on SI, we compared the genotype and allele frequen-
cies of NS with that of regular smokers including both the
Low-ND and High-ND groups. For the effect on ND, we
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compared the genotype and allele frequencies of the Low-
ND group with that of the High-ND group. For individual
SNP association analyses, genotype and allele frequencies
in the three groups were compared by χ2 test or Fisher's
exact test when the expected counts were less than 5 in any
cell of the contingency table. Pairwise linkage disequilib-
rium (LD) was estimated for all subjects by the Haploview
3.2 software [29]. Multi-marker haplotype analyses were
conducted with the COCAPHASE module of the
UNPHASED program [30].
Results
In this study, we genotyped 11 SNPs in the OPRM1 gene.
Nine of the 11 makers were in the Hardy-Weinberg Equi-
librium (HWE). Two SNPs (rs524731 and rs10485057)
showed significant deviation from the HWE, Table 1.
When HWE was examined separately for the 3 subject
groups, none of the 3 groups was significantly deviated
from HWE for rs524731, the P values were 0.182, 0.616
and 0.079 for the NS, Low-ND and High-ND groups
respectively. For rs10485057, the HWE deviation was
caused largely by the High-ND group, the P values for the
NS, Low-ND and High-ND were 0.069, 0.979 and 0.000
respectively. The average scoring rate for the 11 SNPs was
95.6% (94.2–98.7%).
Table 2 summarized the results of allelic and genotypic
association analyses. Three SNPs (rs2075572,
rs10485057 and rs10485058) showed significant differ-
ences (P = 0.036, 0.012 and 0.033, respectively) in geno-
type frequencies between the non-smokers and regular
smokers. One SNP (rs2075572) showed significant differ-
ence in allele frequency between the non-smokers and
regular smokers (P = 0.016). For ND, only one SNP
(rs10485057) reached nominal significance (P = 0.0297).
The non-synonymous marker, rs1799971, was not signif-
icant for SI or ND.
Pairwise LD estimates were listed in Table 3, with D' listed
below the diagonal and r2 above the diagonal. These anal-
yses indicated that there was only one LD block, covering
markers 6–11. From markers 1 to 4, most pairwise LDs
were low. However, several markers, i.e., 1, 3 and 5, or
rs1799971, rs524731 and rs9479757, were in high LD
with markers 6–11 individually. Based on this LD struc-
ture, we conducted multi-marker haplotype analyses
using only the markers showing substantial pairwise LDs.
The markers included in these analyses were markers 1, 3,
5, and 6 to 11. Of these analyses, several combinations
reached or approached nominal significance. The most
significant combination was combination 5-6-7 or
rs9479757-rs2075527-rs10485057, with global P values
of 0.0021 and 0.0514 for SI and ND respectively, Table 4.
In this combination, there were two haplotypes contribut-
ing to elevated risks to tobacco smoking: Haplotype 1-2-
1, or G-C-A, had a frequency of 0.363 in the regular smok-
ers and that of 0.307 in the non-smokers (P = 0.0373),
and haplotype 1-2-2, or G-C-G, was observed only in the
regular smokers (frequency = 0.013, P = 0.0023). For ND,
only the minor haplotype 1-2-2 was significant (the fre-
quency in the High-ND group was 0.022, that in the Low-
ND group was 0.002, P = 0.010). By comparing the pat-
terns of association, it was clear that haplotype 1-2-2 asso-
ciated with both SI and ND, while haplotype 1-2-1 was
associated only with SI. The most abundant haplotype, 1-
1-1 for combination 5-6-7 was significantly underrepre-
sented in the regular smokers (P = 0.0167). Combination
1-3-5-6-7 produced similar results as that of combination
5-6-7. The P values for the global and individual haplo-
type tests were all comparable. These results indicated that
the major risk haplotype defined by markers 5–7
extended to marker 1 in exon 1, the non-synonymous
Asn40Asp polymorphism. This risk haplotype carried the
A (Asn) allele.
Table 1: Marker characteristics
Marker name Marker ID Distance between SNPs 
(bp)
Polymorphism Minor allele Minor allele 
frequency
HWE p value Function
rs1799971 1 0 A/G G 0.124 0.0906 Asn40Asp
rs510769 2 1,472 A/G A 0.267 0.4844 intron
rs524731 3 13,073 A/C A 0.236 0.0051 intron
rs1381376 4 18,166 A/G A 0.161 0.2753 intron
rs9479757 5 18,086 A/G A 0.088 0.7725 intron
rs2075572 6 660 C/G C 0.438 0.6936 intron
rs10485057 7 1,251 A/G G 0.097 0.0000 intron
rs9322447 8 11,065 A/G A 0.493 0.1692 intron
rs609148 9 6,694 C/T C 0.260 0.6886 intron
rs648893 10 7,614 C/T T 0.264 0.2524 intron
rs10485058 11 6,586 A/G G 0.102 0.0679 intron
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Discussion
The evidence from animal experiments, treatment
response and linkage study suggests that OPRM1 may be
a gene contributing to the liability of tobacco smoking
and nicotine dependence. In this study, we conduct asso-
ciation analyses to test whether the OPRM1 gene is asso-
ciated with SI and ND. We use a 3-group design to
compare the genotypic and allelic distribution of 11 SNPs
between the non-smokers and regular smokers and that
between the Low- and High-ND smokers. We find that
three SNPs show genotypic associations with SI and only
one SNP is associated with ND. In haplotype analyses, a
core region covered by 3-marker combination 5-6-7
(rs9479757-rs2075572-rs10485057) reaches global sig-
nificance for smoking initiation. A major haplotype, 1-2-
1 or G-C-A, is overrepresented in the regular smokers as
compared with the non-smokers. A minor haplotype for
the same marker combination, 1-2-2 or G-C-G, is signifi-
cantly associated with both SI and ND. Since the fre-
quency of the minor haplotype is relatively low (0.013–
0.026), there is a chance that this haplotype may be an
artifact of the haplotype reconstruction program. It is well
known that haplotypes with low frequencies have much
higher error rate. On the other hand, the association of the
major haplotype 1-2-1 is likely true. In fact, this haplotype
remains significant when we restrict the analyses to those
haplotypes observed at least once in our data (frequencies
were 0.370 and 0.311 for the smokers and non-smokers,
and P = 0.04084). This haplotype seems to extend to the
first exon, carrying the A allele (Asn) of the Asp40Asn pol-
ymorphism.
Several studies have shown that the μ-opioid receptor is
involved in the reinforcing effects of drugs. The most
extensively studied variation in OPRM1 is Asn40Asp
(rs1799171), but the findings are not consistent [31,32].
Asn40Asp is an A/G transition at the 118th nucleotide of
the coding sequence, causing an amino acid change at
position 40 from asparagine (Asn) to aspartate (Asp). This
change leads to the loss of a putative N-glycosylation site
Table 3: Pairwise LD of the typed SNPs*
rs179997
1
rs51076
9
rs52473
1
rs138137
6
rs947975
7
rs207557
2
rs1048505
7
rs932244
7
rs60914
8
rs64889
3
rs1048505
8
rs1799971 0.00 0.02 0.00 0.00 0.08 0.01 0.10 0.05 0.05 0.02
rs510769 0.03 0.00 0.16 0.00 0.00 0.00 0.01 0.00 0.00 0.00
rs524731 0.59 0.01 0.00 0.28 0.01 0.22 0.01 0.07 0.06 0.02
rs1381376 0.15 0.73 0.01 0.00 0.01 0.01 0.02 0.00 0.00 0.01
rs9479757 0.55 0.20 0.93 0.22 0.11 0.84 0.09 0.03 0.03 0.00
rs2075572 0.86 0.12 0.18 0.10 0.91 0.10 0.79 0.43 0.41 0.11
rs10485057 0.62 0.13 0.80 0.30 0.98 0.83 0.09 0.02 0.01 0.01
rs9322447 0.86 0.17 0.16 0.13 0.94 0.98 0.86 0.36 0.35 0.14
rs609148 1.00 0.16 0.79 0.01 1.00 0.97 0.63 0.99 0.95 0.04
rs648893 1.00 0.08 0.71 0.05 0.92 0.95 0.56 0.98 0.98 0.04
rs10485058 0.88 0.06 0.57 0.17 0.43 0.93 0.75 0.94 0.86 0.82
* Below diagonal, D'; above diagonal r2
Table 2: Single marker association analyses
Number of genotypes in the three groups Genotypic Allelic
NS Low-ND High-ND SI ND SI ND
Marker name 11 12 22 11 12 22 11 12 22 P-Value P-Value P-Value P-Value
rs1799971 187 46 5 161 49 3 173 41 7 0.891 0.273 0.628 0.836
rs510769 130 82 11 121 74 9 133 73 9 0.828 0.867 0.337 0.940
rs524731 141 78 17 107 63 12 129 64 16 0.988 0.681 0.895 0.758
rs1381376 168 65 7 147 62 5 161 60 4 0.278 0.617 0.806 0.489
rs9479757 195 40 2 169 37 2 190 31 2 0.930 0.539 0.776 0.299
rs2075572 83 121 33 54 102 38 65 101 51 0.036 0.441 0.016 0.797
rs10485057 196 40 2 170 31 5 192 19 13 0.012 0.030 0.655 0.964
rs9322447 62 125 43 44 116 48 53 103 59 0.135 0.269 0.067 0.900
rs609148 131 86 14 112 86 11 113 85 17 0.727 0.510 0.409 0.546
rs648893 134 87 14 105 87 10 110 92 16 0.343 0.597 0.233 0.526
rs10485058 164 60 3 154 45 7 177 35 7 0.033 0.293 0.354 0.170
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in the extracellular region. The Asp40 allele is associated
with higher β-endorphin affinity, lower blood cortisol lev-
els and higher aggressive threat scores as compared to the
Asn40 allele. A recent meta-analysis including 28 distinct
samples and over 8000 subjects concludes that this poly-
morphism does not increase the risk of substance depend-
ence [33]. In our study, this polymorphism itself is not
significant. However, we do notice that this polymor-
phism is in high LD with the core markers defining the
associations with both SI and ND. Marker combination 1-
3-5-6-7 produces very similar p values as that observed
with the core markers (see Table 4, comparing combina-
tions 1-3-5-6-7 and 5-6-7). These results suggest that the
Asn40Asp mutation is not itself causative. The associa-
tions observed in some studies are likely a reflection of its
high LD with other causative variant(s) not yet identified.
In a recent study of alcohol dependence, this Asn40Asp
polymorphism is not associated the phenotypes [19].
Similar to our study, while this polymorphism is parti-
tioned in a different LD block, it does share substantial LD
with a risk haplotype found in a separate LD block. Since
several markers (rs1799971, rs609148 and rs648893) in
the alcohol dependence study are also typed in our study,
this allows us to compare the 3 marker haplotype directly.
We find that the extended risk haplotype for SI in our sam-
ple is 1-1-1-2-1-2-2-2 or A-C-G-C-A-A-C-T for markers 1-
3-5-6-7-8-9-10 or rs1799971-rs524731-rs9479757-
rs2075572-rs10485057-rs9322447-rs609148-rs648893.
Extracting markers 1-9-10 from this extended haplotype,
we have 1-2-2 or A-C-T for rs1799971- rs609148-
rs648893. This overlaps with one of the risk haplotypes,
A-A-C-C-T for markers rs1799971-rs3823010-rs495491-
rs609148-rs648893, identified in the alcoholism study.
Given the high comorbidity between alcohol drinking
and tobacco smoking, this finding is interesting. Because
the 5' end of the gene is not in high LD for those markers
we typed in our study, we cannot be certain whether the
same risk haplotype underlies the risks for both alcohol-
ism and tobacco smoking. Further studies with more
markers at the 5' end of the gene are necessary to clarify
this issue.
There are several factors contributing to false positives in
case control studies, including population stratification,
sample size and genotyping error. In our study, we have
taken measurements to reduce these risks. We genotyped
unlinked microsatellite markers to assess potential strati-
fication and used reasonable sample sizes. We examined
HWE for all SNPs. For those two SNPs showing departure
from HWE, we checked each subject groups separately.
Only one (rs10485057) of these two SNPs involves in the
core risk haplotype. For this marker, HWE deviation is
caused largely, if not exclusively, by the High-ND smok-
ers. This case-specific HWE deviation, by itself, can be
interpreted as an association [34,35]. Multiple testing is
another source of false positives. In this study, none of the
tests would survive Bonferroni correction.
Since many of these tests are correlated (many SNPs are in
substantial LD and there is overlap of markers in multi-
marker analyses), Bonferroni correction seems excessive
in this case. Based on this rationale, we decide to use per-
mutation tests to obtain empirical p values for the multi-
marker haplotype tests. With 10,000 permutations, com-
binations 5-6-7, 5-6-7-8 and 1-3-5-6-7 remain significant
for SI (p = 0.0090, 0.0114 and 0.0259 respectively). Based
on these results, we may reasonably conclude that
OPRM1 is associated with smoking initiation. Whether
Table 4: Multi-marker haplotype analyses
Marker 
Combination
Global P 
Value*
Risk 
Haplotype
Case 
Count
Case 
Frequency
Control 
Count
Control 
Frequency
Odds 
Ratio
χ2 Risk Haplotype 
P Value
Smoking Initiation
5-6-7 0.0022 1-2-1 321.9 0.363 149.6 0.307 1.3 4.34 0.0373
1-2-2 11.4 0.013 0.0 0.000 ∞ 9.30 0.0023
5-6-7-8 0.0031 1-2-1-2 318.2 0.358 146.6 0.301 1.3 4.74 0.0294
1-2-2-2 11.7 0.013 0.0 0.000 ∞ 9.66 0.0019
1-3-5-6-7 0.0035 1-1-1-2-1 282.2 0.318 124.7 0.256 1.6 4.22 0.0400
1-1-1-2-2 10.16 0.011 0.0 0.000 ∞ 8.37 0.0038
Nicotine Dependence
5-6-7 0.0514 1-2-2 9.9 0.022 1.2 0.003 8.3 6.61 0.0102
5-6-7-8 0.0630 1-2-2-2 10.0 0.026 1.0 0.003 8.8 7.09 0.0077
* The empirical p values obtained from 10,000 permutations for combinations 5-6-7, 5-6-7-8 and 1-3-5-6-7 for SI were 0.0090, 0.0114 and 0.0259 
respectively.
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OPRM11 is associated with nicotine dependence is less
clear. Further studies with independent samples are neces-
sary to resolve these issues.
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